140 filings
Page 5 of 7
8-K
tlhkjnr6m26ehk0j10j
7 Dec 18
Entry into a Material Definitive Agreement
5:13pm
8-K
v8u5z xh8c5t
6 Dec 18
Fibrogen Appoints Maykin Ho, PH.D., to Board of Directors
6:09am
8-K
q26piz6gh v2t9ggpq
8 Nov 18
FIBROGEN REPORTS third QUARTER 2018 FINANCIAL RESULTS
4:05pm
8-K
429qp712jf7rgmv
30 Oct 18
Other Events
8:01am
8-K
pecb s67tzhldzrgnk8u
26 Oct 18
Other Events
12:00am
8-K
c7kjd57e97ggq rj
1 Oct 18
Other Events
12:00am
8-K
qakt7 emlx00ty6
20 Sep 18
Other Events
8:30am
8-K
8dunwbq
12 Sep 18
Fibrogen Receives Fast Track Designation from the U.s. Fda for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
12:00am
8-K
x8rl 2vl5d190enslpr
7 Aug 18
Fibrogen Reports Second Quarter 2018 Financial Results
12:00am
8-K
nzouy6aqrzuv fhcnkj
8 Jun 18
Regulation FD Disclosure
5:27pm
8-K
4fmg32bni4w 4kpbcclu
7 Jun 18
Other Events
7:31am
8-K
ppf1on swa
6 Jun 18
Submission of Matters to a Vote of Security Holders
4:09pm
8-K
54aabdf0l14bznnjj2i8
4 Jun 18
Demonstrates Enhanced Rate of Surgical Resection with Pamrevlumab in Patients with Previously Unresectable Disease
12:00am
8-K
96n977q
31 May 18
Astellas and FibroGen Announce Topline Results
8:00am
8-K
dd6npufw
21 May 18
Fibrogen Presents Latest Data from Praise Phase 2B Study of
5:04pm
8-K
xa9tyu60fg1pk
9 May 18
Fibrogen Reports First Quarter 2018 Financial Results
4:05pm
8-K
4ypnzkchoedy7o1
1 Mar 18
Other Events
12:00am
8-K
tpiall5ytkv
27 Feb 18
FibroGen Reports Fourth QUARTER and FULL YEAR 2017 Financial Results
12:00am
8-K
29e0utn861spai9eg
16 Feb 18
Departure of Directors or Certain Officers
12:00am
8-K
c9k8c7
8 Jan 18
Regulation FD Disclosure
12:00am